FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks

With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

AnalystConsensusTarget has decreased revenue growth from 23.3% to 20.8% and increased future PE multiple from 42.7x to 51.3x.